Core Viewpoint - Hutchison China MediTech (00013) has seen its stock price increase by over 20% in the month, with a current rise of 3.68% to HKD 24.8, and a trading volume of HKD 142 million, following the publication of SACHI III trial results in The Lancet [1] Group 1: Company Developments - Hutchison China MediTech announced the results of the SACHI III trial, which studied the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR tyrosine kinase inhibitor (TKI) treatment [1] - The SACHI trial results indicate that the combination therapy of savolitinib, a potent and selective oral MET TKI co-developed with AstraZeneca, and osimertinib, an irreversible third-generation EGFR TKI, has shown promising outcomes [1] - Based on the data from the SACHI study, the combination therapy is expected to receive approval in China by June 2025 [1]

Core Viewpoint - Homeland Uranium Corp. has terminated its investor relations services agreement with HoldCo Markets Advisory Inc. and has no intention to engage HCM for future services [4][7]. Group 1: Agreement Details - The HCM Agreement was established on January 24, 2025, for a one-year term, during which HCM was to provide research, coverage reports, and social media services [1][3]. - The total cash fee paid to HCM for the services was $33,600, paid in four equal quarterly installments [3]. Group 2: Termination and Compliance - The Company terminated the HCM Agreement on September 18, 2025, and paid the final installment on the termination date [4]. - The HCM Agreement did not receive prior approval from the TSX Venture Exchange before its termination [4]. - The Company did not disclose the HCM Agreement in its Filing Statement dated February 28, 2025, as it did not consider it material at that time [7]. Group 3: HCM Background - HCM is a Canadian firm specializing in investment management for the junior/mid-cap metals and mining sector, providing research exposure to companies lacking institutional coverage [2]. - HCM's principal holds 166,667 common shares and 83,333 warrants of the Company, acquired through a private placement offering [5][6].

Core Viewpoint - Hutchison China MediTech Limited (00013) has seen its stock price increase by 2.39% to HKD 23.98 following the announcement of positive results from the SACHI III clinical trial published in The Lancet [6]. Group 1: Company Announcement - On January 14, Hutchison China MediTech announced the results of the SACHI III trial, which studies the combination therapy of Savolitinib (沃瑞沙®) and Osimertinib (泰瑞沙®) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR TKI treatment [6]. - The SACHI study focuses on patients with MET amplification and evaluates the efficacy of the combination therapy [6]. Group 2: Drug Information - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [6]. - Osimertinib is an irreversible third-generation EGFR TKI [6]. - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to be approved in China by June 2025 [6].

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently trading at 24.1 HKD, with a transaction volume of 57.28 million HKD, following the announcement of positive results from the SACHI III study published in The Lancet [1] Group 1: Company Announcement - On January 14, Hutchison China MediTech announced the results of the SACHI III study, which evaluates the combination therapy of Savolitinib (赛沃替尼) and Osimertinib (奥希替尼) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have progressed after first-line EGFR TKI treatment [1] - The SACHI study focuses on patients with MET amplification and demonstrates the efficacy of the combination therapy [1] Group 2: Drug Information - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to receive approval in China by June 2025 [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 2.9% at HKD 24.1, with a trading volume of HKD 57.28 million, following the announcement of positive results from the SACHI III study published in The Lancet [1] Group 1: Study Announcement - The SACHI III study results involve a combination therapy of Savolitinib (赛沃替尼) and Osimertinib (奥希替尼) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR tyrosine kinase inhibitor (TKI) treatment [1] - Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, and commercialized by AstraZeneca [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Regulatory Approval - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to receive approval in China by June 2025 [1]

Major Events - Longi Technology (09611) plans to globally offer 52.2591 million H-shares from January 14 to January 19 [1] - CK Life Sciences (00013) announced the results of the SACHI III study published in The Lancet [1] - Dongyang Sunshine Pharmaceutical (06887) launched an AI-driven R&D platform targeting the PROTAC mechanism, continuing to deepen its AI strategic layout [1] - Dongyao Pharmaceutical-B (01875) received a cash offer from WuXi AppTec (02268) at a premium of approximately 99%, with resumption of trading on January 15 [1] - Valiant Pharmaceuticals-B (09887) received Fast Track designation from the US FDA for its bispecific antibody, Opalizumab (LBL-024) [1] - Xunqi (03317) entered into a strategic cooperation framework agreement with Jinyong Investment to support digital transformation in investment research, trading, and risk management [1] Operating Performance - CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for 2025, an increase of 38.46% year-on-year [1] - CITIC Bank (00998) reported a net profit attributable to shareholders of 70.618 billion yuan for 2025, a year-on-year increase of 2.98% [1] - China General Nuclear Power New Energy (01811) completed a cumulative power generation of 19,000 GWh in 2025, a decrease of 0.8% year-on-year [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 106.21 billion yuan for 2025 [1] - WuXi AppTec (02268) issued a profit warning, expecting a net profit growth of over 38% year-on-year for 2025 [1] - Jinyu Group (02009) issued a profit warning, anticipating a net loss attributable to shareholders of 900 million to 1.2 billion yuan for 2025 [1] - Saijing Technology (00580) issued a profit alert, expecting a net profit increase of approximately 30.0% for 2025 [1] - Beijing Beichen Industrial Co., Ltd. (00588) issued a profit warning, expecting a net loss attributable to shareholders of 2.696 billion to 3.38 billion yuan for 2025 [1]

Company News - CITIC Securities (06030.HK) reported a revenue of RMB 74.83 billion for the fiscal year 2025, representing a year-on-year increase of 28.75%, and a net profit of RMB 30.05 billion, up 38.46% year-on-year [2] - CITIC Bank (00998.HK) announced a total revenue of RMB 212.48 billion for 2025, a slight decrease of 0.55% year-on-year, while net profit increased by 2.98% to RMB 70.62 billion [2] - Beijing North Star Industrial (00588.HK) expects to continue reporting losses for the fiscal year ending December 31, 2025 [3] - Yuexiu Property (00123.HK) reported a cumulative contract sales amount of approximately RMB 106.21 billion for 2025, a decline of about 7.3% year-on-year, achieving 88.1% of its sales target [3] - Jiao Ge Peng You Holdings (01450.HK) achieved a total GMV of approximately RMB 6.49 billion in Q4 2025, a year-on-year increase of about 4.34%, with a cumulative GMV of RMB 16.02 billion for the year, up 6.23% [3] - Sai Jing Technology (00580.HK) anticipates a revenue of approximately RMB 2.25 billion for 2025, reflecting a year-on-year increase of about 40% due to increased revenue from flexible transmission business [3] - China General Nuclear Power New Energy (01811.HK) reported a cumulative power generation of 19,000 GWh for 2025, a decrease of 0.8% year-on-year, with variations in different energy sources [3] - Morning News Technology (02000.HK) reported an unaudited revenue of HKD 397 million for 2025, a decrease of 7.4% year-on-year [3] Financing and Buyback Activities - Chow Tai Fook Enterprises (00659.HK) applied for the registration of debt financing instruments totaling no more than RMB 5 billion [7] - Tencent Holdings (00700.HK) repurchased 1.006 million shares at a cost of approximately HKD 636 million, with repurchase prices ranging from HKD 626 to HKD 638 [7] - Xiaomi Group-W (01810.HK) repurchased 4 million shares for approximately HKD 151 million, with repurchase prices between HKD 37.61 and HKD 42.50 [7] Research and Development - Hutchison China MediTech (00013.HK) announced the publication of SACHI III study results in The Lancet [4] - Laka Pharmaceuticals-B (02105.HK) had its clinical trial application for the new drug LAE118 accepted by the U.S. FDA [5] Other News - Yuanxu Technology (08637.HK) announced a short suspension of trading starting January 14, pending the release of insider information [6] - Haidilao (06862.HK) redeemed USD 600 million of its 2.150% notes due in 2026 [2]

Core Viewpoint - The announcement by Hutchison China MediTech Limited (和黄医药) regarding the publication of the SACHI III study results in The Lancet highlights the efficacy of the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive non-small cell lung cancer patients with MET amplification who have progressed after first-line TKI treatment [1][2]. Group 1: Study Results - The SACHI study demonstrates that the combination of savolitinib (a potent MET TKI) and osimertinib (a third-generation EGFR TKI) significantly improves treatment outcomes for patients with MET amplification [1][2]. - The data from the SACHI study indicates that the combination therapy has been approved in China as of June 2025 [1]. Group 2: Expert Commentary - Professor Lu Shun, a principal investigator of the SACHI study, emphasized that the results provide strong evidence for the effectiveness of the combination therapy in addressing MET amplification, a key resistance mechanism in challenging patient populations [2]. - The study also noted consistent efficacy in patients who had previously received third-generation EGFR TKI treatment, indicating the therapy's potential for a broader patient base [2]. - The combination therapy offers a convenient and well-tolerated all-oral treatment option for patients in need of new therapies [2].

Core Viewpoint - The results of the SACHI III study, which evaluates the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive non-small cell lung cancer patients with MET amplification, have been published in The Lancet, indicating significant clinical benefits [1][2]. Group 1: Study Overview - The SACHI study focuses on the combination of savolitinib (a potent MET TKI) and osimertinib (a third-generation EGFR TKI) for patients who have progressed after first-line EGFR TKI treatment [1]. - The combination therapy has been approved in China for use starting June 2025 based on the data from the SACHI study [1]. Group 2: Clinical Implications - The data from the SACHI study provides strong evidence that the combination therapy significantly improves treatment outcomes for patients with MET amplification and EGFR mutations [2]. - The study highlights the ability of the combination therapy to address MET amplification, a key resistance mechanism, offering clinically meaningful improvements for challenging patient populations [2]. - Notably, consistent efficacy was observed in patients who had previously received third-generation EGFR TKI treatment, indicating the therapy's potential for broader application [2].

Core Insights - The SACHI Phase III trial confirms the efficacy of the savolitinib and osimertinib combination in treating advanced NSCLC patients with MET amplification after prior EGFR-TKI treatment [1][3][4] - The combination received regulatory approval in China in June 2025, indicating a significant advancement in treatment options for this patient population [2][18] Company Overview - HUTCHMED is a biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases, with its first three medicines marketed in China [21] - Savolitinib (ORPATHYS®) is a selective MET TKI developed in collaboration with AstraZeneca, while osimertinib (TAGRISSO®) is a third-generation EGFR TKI [2][9][12] Trial Details - The SACHI trial involved 211 patients, with a median progression-free survival (PFS) of 8.2 months for the combination therapy compared to 4.5 months for chemotherapy, demonstrating a significant improvement [4][5] - The objective response rate (ORR) was 58% for the combination therapy versus 34% for chemotherapy, and the disease control rate (DCR) was 89% compared to 67% [5] Efficacy and Safety - In the third-generation EGFR TKI-naïve subgroup, the median PFS was 9.8 months for the combination versus 5.4 months for chemotherapy, further supporting the treatment's efficacy [6] - The safety profile of the combination was tolerable, with no new safety signals observed, and treatment-emergent adverse events of Grade 3 or above were similar between the two treatment arms [7] Market Context - Lung cancer is the leading cause of cancer death, with NSCLC accounting for 80-85% of cases, and a significant portion of patients exhibiting EGFR mutations [8] - MET amplification is a known resistance mechanism to EGFR TKIs, making the combination of savolitinib and osimertinib a promising strategy for addressing this challenge [8][17]